Randomized trial of intravenous iron-induced hypophosphatemia

JCI insight

Volumn 3, Issue 23, 2018, Pages

  Wolf, Myles ^a,b   Chertow, Glenn M ^a,c   Macdougall, Iain C ^d   Kaper, Robert ^e   Krop, Julie ^e   Strauss, William ^e  

^a Department of Medicine and

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c STANFORD UNIVERSITY   (United States)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

^e AMAG PHARMACEUTICALS INC   (United States)

Author keywords

Calcium; Endocrinology; Hematology

Indexed keywords

CALCITRIOL; CALCIUM; FERRIC CARBOXYMALTOSE; FERRIC ION; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; IRON; MAGNETITE; MALTOSE; PHOSPHATE;

ADULT; BLOOD; CONTROLLED STUDY; FEMALE; HOMEOSTASIS; HUMAN; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; URINE;

ADMINISTRATION, INTRAVENOUS; ADULT; ANEMIA, IRON-DEFICIENCY; CALCITRIOL; CALCIUM; FEMALE; FERRIC COMPOUNDS; FERROSOFERRIC OXIDE; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; IRON; MALE; MALTOSE; MIDDLE AGED; PHOSPHATES; RISK FACTORS;

EID: 85063244190     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.124486     Document Type: Article

References (0)